protein-engineered interleukin-12 XTX301
Term · Oncology and biomedicine · MLC-T-ONC-016264
An engineered form of the human cytokine interleukin-12 (IL-12) in which the IL-12 is conjugated, via a tumor protease-cleavable linker, to a protein-engineered masking domain that prevents the binding of IL-12 to its receptors while in circulation and a half-life extension domain that prolongs circulating half-life, with potential immunomodulatory and antineoplastic activities. Upon administration of protein-engineered IL-12 XTX301, IL-12 is bound to the masking domain and pharmacologically inactive. Upon proteolytic cleavage by matrix metalloproteinases (MMPs) in the tumor microenvironment (TME), active IL-12 is released. IL-12 activates the immune system by promoting the secretion of interferon-gamma (IFN-g) and activating CD8+ T cells, CD4+ T cells and natural killer cells (NKs). The activation and expansion of these immune cells mediate cytolytic immune responses against tumor cells, thereby killing tumor cells and inhibiting tumor cell proliferation. The selective activation in the TME enhances the IL-12-mediated cytolytic responses against tumor cells while sparing the unwanted effects of systemic, peripheral immune activation.
| Identifier | MLC-T-ONC-016264 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | protein-engineered IL-12 XTX301; tumor-activated engineered interleukin 12 XTX301 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-016264",
"term": "protein-engineered interleukin-12 XTX301",
"field": "Oncology and biomedicine",
"definition": "An engineered form of the human cytokine interleukin-12 (IL-12) in which the IL-12 is conjugated, via a tumor protease-cleavable linker, to a protein-engineered masking domain that prevents the binding of IL-12 to its receptors while in circulation and a half-life extension domain that prolongs circulating half-life, with potential immunomodulatory and antineoplastic activities. Upon administration of protein-engineered IL-12 XTX301, IL-12 is bound to the masking domain and pharmacologically inactive. Upon proteolytic cleavage by matrix metalloproteinases (MMPs) in the tumor microenvironment (TME), active IL-12 is released. IL-12 activates the immune system by promoting the secretion of interferon-gamma (IFN-g) and activating CD8+ T cells, CD4+ T cells and natural killer cells (NKs). The activation and expansion of these immune cells mediate cytolytic immune responses against tumor cells, thereby killing tumor cells and inhibiting tumor cell proliferation. The selective activation in the TME enhances the IL-12-mediated cytolytic responses against tumor cells while sparing the unwanted effects of systemic, peripheral immune activation.",
"synonyms": [
"protein-engineered IL-12 XTX301",
"tumor-activated engineered interleukin 12 XTX301"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/protein-engineered-interleukin-12-xtx301/"
}
Record 13,764 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.